Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
Last trade$7.08
Day change-$0.265 (-3.61%)
Day range$6.97 – $7.53
Volume86,749
Market cap$269M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$268.84M
Price / earnings
—
Price / book
6.32×
Price / sales
11.38×
EV / sales
10.16×
EV / EBITDA
-7.1×
Profitability
Earnings per share
-$0.89
Return on assets
-55.87%
Return on equity
-76.42%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.11×
Current ratio
4.54×
Quick ratio
3.7×
Cash ratio
2.76×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$31.67M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PROF, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$9.83M
$2.48M
$5.34M
$5.98M
$5.29M
$2.21M
$2.62M
$4.18M
Cost of revenue
$2.15M
$536K
$1.51M
$1.99M
$1.36M
$593K
$768K
$1.21M
Gross profit
$7.68M
$1.95M
$3.83M
$3.99M
$3.93M
$1.62M
$1.85M
$2.96M
Selling, general and administrative
$9.7M
$7.36M
$6.59M
$7.09M
$7.43M
$9.33M
$8.21M
$6.66M
Research and development
$5.81M
$5.65M
$5.26M
$4.27M
$5.42M
$6.1M
$4.81M
$4.65M
Total operating expenses
$15.5M
$13.01M
$11.85M
$11.36M
$12.84M
$15.42M
$13.02M
$11.31M
Operating income
-$7.82M
-$11.07M
-$8.02M
-$7.37M
-$8.91M
-$13.81M
-$11.17M
-$8.35M
Interest expense
$196K
$0
$377K
$0
$122K
$0
$445K
$0
Income before taxes
-$7.73M
-$9.49M
-$7.03M
-$8.15M
-$7.86M
-$15.63M
-$10.68M
-$5.19M
Income taxes
-$4K
$55K
$25K
$26K
$121K
$64K
$41K
-$238K
Net income
-$7.72M
-$9.54M
-$7.05M
-$8.18M
-$7.98M
-$15.7M
-$10.72M
-$4.95M
Net income attributable to common shareholders
-$7.72M
-$9.54M
-$7.05M
-$8.18M
-$7.98M
-$15.7M
-$10.72M
-$4.95M
EBITDA
-$7.69M
-$10.93M
-$7.92M
-$7.26M
-$8.77M
-$13.67M
-$11M
-$8.11M
Basic earnings per share
-$0.21
-$0.26
-$0.19
-$0.27
-$0.26
-$0.52
-$0.36
-$0.19
Diluted earnings per share
-$0.21
-$0.26
-$0.19
-$0.27
-$0.26
-$0.52
-$0.36
-$0.19
Recent news
Company coverage with links to the original publishers.
Profound Medical reported a quarterly loss of $0.21 per share, missing the consensus estimate of $0.19 loss, with an earnings surprise of -10.53%. Revenue of $9.83 million slightly exceeded expectations by 0.31%, but the company has underperformed the S&P 500 by 21.3% year-to-date. Despite the miss, the stock maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends.
Profound Medical is expected to report a quarterly loss of $0.19 per share with revenues of $9.8 million (up 85.3% YoY) for Q3 2026. With a positive Earnings ESP of +15.79% and Zacks Rank #2 (Buy), the company is positioned to likely beat consensus EPS estimates. However, the stock has missed estimates in recent quarters, delivering a -18.18% surprise last quarter.
Profound Medical (PROF) has gained 0.2% over the past four weeks and currently trades at $5.86. Wall Street analysts have set a mean price target of $11.13, indicating a potential upside of 89.9%. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions. However, the article cautions that price targets alone should not be the sole basis for investment decisions, as analysts often set overly optimistic targets.
Profound Medical (PROF) closed at $7.01 with a mean analyst price target of $11.13, suggesting 58.8% upside potential. The stock has gained 23.4% over the past four weeks. Analysts have revised earnings estimates higher over the last 30 days, and PROF holds a Zacks Rank #2 (Buy) rating. However, the article cautions that price targets can be misleading and should not be the sole basis for investment decisions.
Profound Medical (PROF) surged 21.7% following strong preliminary Q3 2026 revenue guidance of $9.8-10 million, representing 85-89% year-over-year growth and 45-47% above analyst consensus. The company expects gross margins exceeding 70%, signaling improved commercial momentum. However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that the stock's momentum may not sustain without further positive estimate revisions.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.